FT 267
Musculoskeletal Growth Trust Series
Supplement to the Prospectus dated July 29, 1998
Notwithstanding anything to the contrary in the Prospectus, Unit
holders who acquire Units which, as a result of a reduction in the aggregate
underlying value of the Equity Securities, are not subject to an initial sales
charge will be subject to the maximum remaining deferred sales charge
(initially $.35 per Unit). In such case the maximum sales charge may exceed
4.5% of the Public Offering Price per Unit but in no event will the maximum
sales charge exceed 5.5% of the Public Offering Price per Unit.
October 8, 1998
